BCRX Q4 2022 Earnings — BioCryst Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

BCRXBioCryst Pharmaceuticals, Inc.

$2B

Q4 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$80M+68.7% YoY

Gross Profit

$77M96.9% margin

Operating Income

-$46M-58.2% margin

Net Income

-$72M-89.9% margin

EPS (Diluted)

$-0.38

QoQ Revenue Growth

+4.9%

Cash Flow

Operating Cash Flow

-$24M

Free Cash Flow

-$24M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$550M

Total Liabilities

$845M

Stockholders' Equity

-$295M

Cash & Equivalents

$305M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$80M	$47M	+68.7%
Gross Profit	$77M	$47M	+64.8%
Operating Income	-$46M	-$52M	+11.2%
Net Income	-$72M	-$18M	-302.4%

Revenue Segments

Product

$78M98%

Royalty

$1M2%

Collaborative And Other Research And Development

$66,0000%